Avid Bioservices Inc (CDMO)

[investingdog]

<<FDA would not have approved PHIII if 1st line was not good, IMO!>>


Disagree. P3 has been approved based on the trial results and FDA understands that the results would have most likely been better without the dose switching, close to what was originally reported in September.

First line is crucial IMO, if not very good PPS will take a significant dump and will be hard to partner.